[1] TSIROPOULOS I, ANDERSEN M, HALLAS J. Adverse events with use of antiepileptic drugs:a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf, 2009, 18(6):483-491.
[2] FARINELLI E, GIAMPAOLI D, CENCIARINI A, et al. Valproic acid and nonalcoholic fatty liver disease: a possible association?. World J Hepatol, 2015, 7(9):1251-1257.
[3] NAGAI G, ONO S, YASUI-FURUKORI N, et al. Formulations of valproate alter valproate metabolism:a single oral dose kinetic study. Ther Drug Monit, 2009, 31(5):592-596.
[4] KODAMA Y, KODAMA H, KURANARI M, et al. No effect of gender or age on binding characteristics of valproic acid to serum proteins in pediatric patients with epilepsy. J Clin Pharmacol, 1999, 39(10):1070-1076.
[5] SUZUKI Y, ITOH H, ABE T, et al. No effect of co-administered antiepileptic drugs on in-vivo protein binding parameters of valproic acid in patients with epilepsy. J Pharm Pharmacol, 2011, 63(7):976-981.
[6] VIDAURRE J, GEDELA S, YAROSZ S. Antiepileptic drugs and liver disease. Pediatr Neurol, 2017, 77:23-36.
[7] KIANG T K, TENG X W, KARAGIOZOV S, et al. Role of oxidative metabolism in the effect of valproic acid on markers of cell viability, necrosis, and oxidative stress in sandwich-cultured rat hepatocytes. Toxicol Sci, 2010, 118(2):501-509.
[8] DREIFUSS F E, SANTILLI N, LANGER D H, et al. Valproic acid hepatic fatalities:a retrospective review. Neurology, 1987, 37(3):379-385.
[9] DIPAOLA F, MOLLESTON J P, GU J, et al. Antimicrobials and antiepileptics are the leading causes of idiosyncratic drug-induced liver injury in american Children. J Pediatr Gastroenterol Nutr, 2019, 69(2):152-159.
[10] TULLOCH J K, CARR R R, ENSOM M H. A systematic review of the pharmacokinetics of antiepileptic drugs in neonates with refractory seizures. J Pediatr Pharmacol Ther, 2012, 17(1):31-44.
[11] STAR K, EDWARDS I R, Choonara I. Valproic acid and fatalities in children:a review of individual case safety reports in VigiBase. PLoS One, 2014, 9(10):e108970.
[12] O'SULLIVAN A, GIBNEY M J, BRENNAN L. Dietary intake patterns are reflected in metabolomic profiles:potential role in dietary assessment studies. Am J Clin Nutr, 2011, 93(2):314-321.
[13] MISRA A, SINGHAL N, KHURANA L. Obesity, the metabolic syndrome, and type 2 diabetes in developing countries:role of dietary fats and oils. J Am Coll Nutr, 2010, 29(Suppl 3):S289-S301.
[14] SATHIYA P C, BHAVANI K, ANURADHA C V. High-calorie diet inflates steatogenic effects of valproic acid in mice. Toxicol Mech Methods, 2016, 26(2):112-121.
[15] NGUYEN K V, SHARIEF F S, CHAN S S, et al. Molecular diagnosis of Alpers syndrome. J Hepatol, 2006, 45(1):108-116.
[16] SANETO R P, COHEN B H, COPELAND W C, et al. Alpers-Huttenlocher syndrome. Pediatr Neurol, 2013, 48(3):167-178.
[17] HORVATH R, HUDSON G, FERRARI G, et al. Phenotypic spectrum associated with mutations of the mitochondrial polymerase gamma gene. Brain, 2006, 129(Pt 7):1674-1684.
[18] KIANG T K, HO P C, ANARI M R, et al. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype. Toxicol Sci, 2006, 94(2):261-271.
[19] AMINI-SHIRAZI N, GHAHREMANI M H, AHMADKHANIHA R, et al. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients. Toxicol Mech Methods, 2010, 20(8):452-457.
[20] ZHAO M, ZHANG T, LI G, et al. Associations of CYP2C9 and CYP2A6 polymorphisms with the concentrations of valproate and its hepatotoxin metabolites and valproate-induced hepatotoxicity. Basic Clin Pharmacol Toxicol, 2017, 121(2):138-143.
[21] STEWART JD, HORVATH R, BARUFFINI E, et al. Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity. Hepatology, 2010, 52(5):1791-1796.
[22] HYNYNEN J, POKKA T, KOMULAINEN-EBRAHIM J, et al. Variants p. Q1236H and p. E1143G in mitochondrial DNA polymerase gamma POLG1 are not associated with increased risk for valproate-induced hepatotoxicity or pancreatic toxicity:a retrospective cohort study of patients with epilepsy. Epilepsia, 2018, 59(11):2125-2136.
[23] ATEL A R, NAGALLI S. Valproate toxicity. Treasure Island (FL): StatPearls Publishing LLC., 2021 (2021-07-26). https://www. ncbi.nlm.nih.gov/books/NBK560898/.
[24] OGUSU N, SARUWATARI J, NAKASHIMA H, et al. Impact of the superoxide dismutase 2 Val16Ala polymorphism on the relationship between valproic acid exposure and elevation of gamma-glutamyltransferase in patients with epilepsy:a population pharmacokinetic-pharmacodynamic analysis. PLoS One, 2014, 9(11):e111066.
[25] SARUWATARI J, DEGUCHI M, YOSHIMORI Y, et al. Superoxide dismutase 2 Val16Ala polymorphism is a risk factor for the valproic acid-related elevation of serum aminotransferases. Epilepsy Res, 2012, 99(1-2):183-186.
[26] MA L, PAN Y, SUN M, et al. Catalase C-262T polymorphism is a risk factor for valproic acid-induced abnormal liver function in Chinese patients with epilepsy. Ther Drug Monit, 2019, 41(1):91-96.
[27] HAUSER E, SEIDL R, FREILINGER M, et al. Hematologic manifestations and impaired liver synthetic function during valproate monotherapy. Brain Dev, 1996, 18(2):105-109.
[28] MEUNIER L, LARREY D. Drug-induced liver injury: biomarkers, requirements, candidates, and validation. Front Pharmacol, 2019, 10:1482.
[29] CHEN Y, ZHOU J, XU S, et al. Association between the perturbation of bile acid homeostasis and valproic acid-induced hepatotoxicity. Biochem Pharmacol, 2019, 170:113669.
[30] XU S, CHEN Y, MA Y, et al. Lipidomic profiling reveals disruption of lipid metabolism in valproic acid-induced hepatotoxicity. Front Pharmacol, 2019, 10:819.
[31] GODA K, SAITO K, MUTA K, et al. Ether-phosphatidylcholine characterized by consolidated plasma and liver lipidomics is a predictive biomarker for valproic acid-induced hepatic steatosis. J Toxicol Sci, 2018, 43(6):395-405.
[32] LI Z Y, LIU Y, WANG D Z, et al. Clinical significance of the changes of amino acid in children with epilepsy on valproate monotherapy. J Mod Lab Med(现代检验医学杂志), 2017, 32(5):24-27.
[33] LEE M S, JUNG B H, CHUNG B C, et al. Metabolomics study with gas chromatography-mass spectrometry for predicting valproic acid-induced hepatotoxicity and discovery of novel biomarkers in rat urine. Int J Toxicol, 2009, 28(5):392-404.
[34] FERNANDES-FREITAS I, OWEN B M. Metabolic roles of endocrine fibroblast growth factors. Curr Opin Pharmacol, 2015, 25:30-35.
[35] SALMINEN A, KAARNIRANTA K, KAUPPINEN A. Regulation of longevity by FGF21:Interaction between energy metabolism and stress responses. Ageing Res Rev, 2017, 37:79-93.
[36] YANG C, LU W, LIN T, et al. Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress. BMC Gastroenterol, 2013, 13:67.
[37] KIM S H, KIM K H, KIM H K, et al. Fibroblast growth factor 21 participates in adaptation to endoplasmic reticulum stress and attenuates obesity-induced hepatic metabolic stress. Diabetologia, 2015, 58(4):809-818.
[38] WOO YC, XU A, WANG Y, et al. Fibroblast growth factor 21 as an emerging metabolic regulator:clinical perspectives. Clin Endocrinol (Oxf), 2013, 78(4):489-496.
[39] XU X, GUO C, LIANG X, et al. Potential biomarker of fibroblast growth factor 21 in valproic acid-treated livers. Biofactors, 2019, 45(5):740-749.
[40] CHEN ZJ, WANG XD, WANG HS, et al. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy. Seizure, 2012, 21(2):110-117.
[41] ZHOU X, CHEN S, ZONG CF, et al. Correlation analysis of valproic acid and its metabolites to hepatotoxicity. J Pharm Pract(药学实践杂志), 2020, 38(3):273-276.
[42] YAMADA H, SUZUKI K, ICHINO N, et al. Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver. Clin Chim Acta, 2013, 424:99-103.
[43] TONG V, TENG XW, CHANG TK, et al. Valproic acid I:time course of lipid peroxidation biomarkers, liver toxicity, and valproic acid metabolite levels in rats. Toxicol Sci, 2005, 86(2):427-435.